Manifestasi Okular Coronavirus Disease 2019 (COVID-19): Klinis dan Pencegahan
DOI:
https://doi.org/10.55175/cdk.v47i8.574Kata Kunci:
Coronavirus, COVID-19, okular, SARS-CoV-2Abstrak
Pandemi global Coronavirus Disease 2019 (COVID-19) memiliki gejala utama batuk, demam, kelelahan, sesak napas, dan gejala respiratori lainnya. Didapatkan kasus pasien COVID-19 yang memiliki keluhan okular seperti konjungtivitis. Angiotensin-converting enzyme 2 (ACE2), yang merupakan reseptor SARS-CoV-2, juga didapatkan pada sel epitel konjungtiva dan kornea manusia, sehingga memungkinkan transmisi melalui okular. Tatalaksana gejala okular pada COVID-19 hingga saat ini masih terus dikembangkan serta diuji coba.
The Global Coronavirus Disease 2019 (COVID-19) pandemic has cough, fever, fatigue, shortness of breath, and other respiratory symptoms as the main symptoms. There were cases of COVID-19 patients with ocular complaints such as conjunctivitis. Angiotensin-converting enzyme 2 (ACE2) – SARS-CoV-2 receptor, is also found in human conjunctival and corneal epithelial cells, thus allowing ocular transmission. Treatment for ocular symptoms in COVID-19 are still being developed and tested.
Unduhan
Referensi
World Health Organization. Global update on coronavirus disease [Internet]. 2020. Available from: https://www.who.int/
Wang F-S, Zhang C. What to do next to control the 2019-nCoV epidemic? Lancet. 2020;395(10222):391-3.
Loon S-C, Teoh SCB, Oon LLE, Se-Thoe SY, Ling AE, Leo YS, et al. The severe acute respiratory syndrome coronavirus in tears. British J Ophthalmol. 2004;88(7):861–3. doi:10.1136/bjo.2003.035931.
Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: Is faecal & oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol. 2020;5(4):335-7
Leong HN, Chan KP, Khan AS, Oon L, Se-Thoe SY, Bai XL, et al. Virus-specific RNA and antibody from convalescent-phase SARS patients discharged from hospital.cEmerg Infect Dis. 2004;10(10):1745-50
Sun C, Wang Y, Liu G, Liu Z. Role of the eye in transmitting human coronavirus: What we know and what we do not know. Frontiers in Public Health 2020;8:155.
Belser JA, Rota PA, Tumpey TM. Ocular tropism of respiratory viruses. Microbiol Mol Biol Rev. 2013;77(1):144-56.
Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA cOphthalmol. 2020;138(5):575.doi: 10.1001/jamaophthalmol.2020.1291
Zhou Y, Zeng Y, Tong Y, Chen C. Ophthalmologic evidence against the interpersonal transmission of 2019 novel coronavirus through conjunctiva.medRxiv. 2020. doi: https://doi.org/10.1101/2020.02.11.20021956.
Lu C, Liu X, Jia Z. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet 2020; 395(10224):39. doi: 10.1016/S0140-6736(20)30313-5.[PubMed: 32035510]
Chen L, Deng C, Chen X, Zhang X, Chen B, Yu H, et.al. Ocular manifestations and clinical characteristics of 534 cases of COVID-19 in China: A cross-sectional study. 2020. medRxiv preprint doi: https://doi.org/10.1101/2020.03.12.20034678
Azari AA, Barney NP. Conjunctivitis. JAMA2013;310(16): 1721.
Usher P, Keefe J, Crock C, Chan E. Appropriate prescribing for viral conjunctivitis. Aust Fam Physician. 2014;43(11):748-9
Shiota H, Ohno S, Aoki K, Azumi A, Ishiko H, Inoue Y, et al. [Guideline for the nosocomial infections of adenovirus conjunctivitis]. Nippon Ganka Gakkai Zasshi.2009;113(1):25-46
Li JO, Lam DSC, Chen Y, Ting DSW. Novel Coronavirus disease 2019 (COVID-19): The importance of recognising possible early ocular manifestation and using protective eyewear. Br J Ophthalmol 2020;104:297-8.
Hamid S, Mir MY, Rohela GK. Novel coronavirus disease (COVID-19): A pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbes New Infect. 2020;35. 10.1016/j.nmni.2020.100679
Ulhaq ZS, Soraya GV. The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/fluid. Graefes Arch. Clin Exp Ophthalmol. 2020. https://doi.org/10.1007/s00417-020-04695-8
Swerdlow DL, Finelli L. Preparation for possible sustained transmission of 2019 Novel Coronavirus: Lessons from previous epidemics. JAMA. 2020:10.1001/jama.2020.1960.
Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocular Immunol Inflammation. 2020;28(3):391-5.
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chinese J Epidemiol. 2020;41(2):145-51
Seah I, Su X, Lingam G. Revisiting the dangers of the coronavirus in the ophthalmology practice. Eye. 2020;34(7):1155-7
Zhu X, Liu Q, Du L, Lu L, Jiang S. Receptor-binding domain as a target for developing SARS vaccines. J Thoracic Dis. 2013;5:142-8.
Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018;100:163–88.
Vassilara F, Spyridaki A, Pothitos G, Deliveliotou A, Papadopoulos A. A rare case of human coronavirus 229E associated with acute respiratory distress syndrome in a healthy adult. Case Rep Infect Dis. 2018;2018:6796839.
Weber R, Keerl R, Schaefer S, Della Rocca R. Atlas of lacrimal surgery. Berlin: Springer; 2007.
Gralinski LE, Baric RS. Molecular pathology of emerging corona- virus infections. J Pathol. 2015;235(2):185–95.
Liu L, Sun Y, Pan X, Shen W, Liu ZY, Liu YP. Expression of SARS coronavirus S proteinfunctional receptor angiotensin-converting enzyme 2 in human cornea and conjunctiva. Chin Ophthal Res. 2004;22(6):561-4
Sun Y, Liu L, Pan X, Jing M. Mechanism of the action between the SARS- CoV S240 protein and the ACE2 receptor in eyes. Int J Ophthalmol (Guoji Yankezazhi). 2006;6(4):783-6.
Zhang X, Chen X, Chen L, Deng C, Zou X, Liu W, et al. The evidence of SARS-CoV-2 infection on ocular surface. The Ocular Surface 2020;18(3):360-2.
Xia J, Tong J, Liu M, Shen Y. Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Medical Virol2020;92(6):589-94.
Chen L, Liu M, Zhang Z, Qiao K, Huang T, Chen M, et al. Ocular manifestations of a hospitalized patient with confirmed 2019 novel coronavirus disease.Br J Ophthalmol 2020;0:1–4. doi:10.1136/bjophthalmol-2020-316304
Napoli PE, Nioi M, d’Aloja E, Fossarello M. The ocular surface and the coronavirus disease 2019: Does a dual ‘ocular route’ exist? J Clin Med. 2020;9:1269; doi:10.3390/jcm9051269
Chan JF-W, Kok K-H, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-36. https://doi.org/10.1080/22221751.2020.1719902
Deng C, Yang Y, Chen H, Chen W, Chen Z, Ma K, et al. Ocular detection of SARS-CoV-2 in 114 cases of COVID-19 pneumonia in Wuhan, China: An observational study (2/19/2020). https://doi. org/10.2139/ssrn.3543587
Colavita F, Lapa D, Carletti F, Lalle E, Bordi L, Marsella P, et al. SARS-CoV-2 Isolation from ocular secretions of a patient with COVID-19 in Italy with prolonged viral RNA detection. Ann Intern Med. 2020. DOI: 10.7326/M20-1176
Chodosh J, Holland GN, Yeh S. Important coronavirus update for ophthalmologist [Internet]. 2020. Available from: https://www.aao.org/headline/alert-importantcoronavirus-context
Khalali JS, Zhu H, Amanda Mak NS, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for evaluation concerning COVID-19 [Internet]. 2020. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228408/
Centers for Disease Control and Prevention. 2019 Novel Coronavirus, Wuhan, China. 2020
Evans M. Wuhan Coronavirus: What you need to know. WebMD [Internet]. 2020. Available from: https://www.webmd.com/lung/news/20200303/coronaviruswhat-you-need-to-know
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-192. N Engl J Med. 2020;10:1-10. DOI: 10.1056/NEJMoa2007016
Femere RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. 2020. BMJ 2020;369:1432 doi: 10.1136/bmj.m1432
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel nonrandomized clinical trial. Internat J Antimicrob Agents. 2020;56(1):105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med 2020; 382:1708-20
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2020 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
